Targeting Treg Cells In Situ: Emerging Expansion Strategies for (CD4+CD25+) Regulatory T Cells

被引:13
作者
Shatry, Alwi [1 ]
Chirinos, Jackeline [1 ]
Garin, Michael A. [1 ]
Jones, Monica [1 ]
Levy, Robert B. [1 ]
机构
[1] Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL USA
关键词
In situ manipulation; Treg cells; CD4(+)CD25(+); Expansion strategies; Immune regulation; Marrow allograft resistance; VERSUS-HOST-DISEASE; FOXP3; EXPRESSION; DENDRITIC CELLS; VITRO EXPANSION; INTRAVENOUS IMMUNOGLOBULIN; MONOCLONAL-ANTIBODY; CANCER-PATIENTS; VIVO; IL-2; TOLERANCE;
D O I
10.1016/j.bbmt.2009.06.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recognition of the ability of CD4(+)FoxP3(+) T cells (Treg) to influence the generation of peripheral immune responses has engendered enthusiasm for the development of strategies utilizing these cells to regulate immune responses in clinically important settings including transplantation, autoimmunity and cancer. A number of studies have reported effective regulation utilizing ex-vivo expansion approaches and subsequent transfer of Treg populations in experimental models. This commentary discusses recently emerging strategies to activate and expand Treg cells in situ which include antibodies, antigen presenting cells and the use of IL2/anti-IL2 antibody complex. The development of reagents which can stimulate and/or remove Treg cells in situ would represent an important advance towards facilitating new opportunities to harness this compartment for the augmentation of 'wanted' or suppression of 'unwanted' immune responses. Simultaneous targeting of multiple molecules on Treg cells may ultimately enable more effective control of this regulatory sector.
引用
收藏
页码:1239 / 1243
页数:5
相关论文
共 46 条
[1]   IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients [J].
Ahmadzadeh, M ;
Rosenberg, ST .
BLOOD, 2006, 107 (06) :2409-2414
[2]   Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells [J].
Barao, I ;
Hanash, AM ;
Hallett, W ;
Welniak, LA ;
Sun, K ;
Redelman, D ;
Blazar, BR ;
Levy, RB ;
Murphy, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (14) :5460-5465
[3]   Regulatory T cells in ovarian cancer: Biology and therapeutic potential [J].
Barnett, B ;
Kryczek, I ;
Cheng, P ;
Zou, WP ;
Curiel, TJ .
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2005, 54 (06) :369-377
[4]   Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells [J].
Battaglia, M ;
Stabilini, A ;
Roncarolo, MG .
BLOOD, 2005, 105 (12) :4743-4748
[5]   Host CD4+ CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT [J].
Bayer, Allison L. ;
Jones, Monica ;
Chirinos, Jackeline ;
de Armas, Lesley ;
Schreiber, Taylor H. ;
Malek, Thomas R. ;
Levy, Robert B. .
BLOOD, 2009, 113 (03) :733-743
[6]   Protection from graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibody [J].
Beyersdorf, Niklas ;
Ding, Xin ;
Blank, Gregor ;
Dennehy, Kevin M. ;
Kerkau, Thomas ;
Huenig, Thomas .
BLOOD, 2008, 112 (10) :4328-4336
[7]   Selective stimulation of T cell subsets with antibody-cytokine immune complexes [J].
Boyman, O ;
Kovar, M ;
Rubinstein, MP ;
Surh, CD ;
Sprent, J .
SCIENCE, 2006, 311 (5769) :1924-1927
[8]   In vitro expansion improves in vivo regulation by CD4+CD25+ regulatory T cells [J].
Chai, Jian-Guo ;
Coe, David ;
Chen, Daxin ;
Simpson, Elizabeth ;
Dyson, Julian ;
Scott, Diane .
JOURNAL OF IMMUNOLOGY, 2008, 180 (02) :858-869
[9]   CD4+CD25+ immunoregulatory T cells:: New therapeutics for graft-versus-host disease [J].
Cohen, JL ;
Trenado, A ;
Vasey, D ;
Klatzmann, D ;
Salomon, BL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (03) :401-406
[10]   Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells [J].
Dannull, J ;
Su, Z ;
Rizzieri, D ;
Yang, BK ;
Coleman, D ;
Yancey, D ;
Zhang, AJ ;
Dahm, P ;
Chao, N ;
Gilboa, E ;
Vieweg, J .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (12) :3623-3633